Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection could ease sleep apnea in obese patients

NCT ID NCT06994650

Recruiting now Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests an injectable drug called HRS9531 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The study aims to see if the drug reduces the number of breathing pauses during sleep and helps with weight loss over 52 weeks. Participants are randomly assigned to receive either the drug or a placebo injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HRS9531 injection
What this could lead to
If successful, this could offer a new treatment option to reduce sleep apnea severity and aid weight loss in obese patients already using a breathing machine.
What could go wrong
This is a phase 3 trial, but results may not apply to all patients. Side effects from the drug are possible, and the benefit over placebo is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SUBJECTS WITH MODERATE-TO-SEVERE OSA AND OBESITY WHO ARE ON PAP THERAPY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.